Erich Studerus
Psychologist and Scientific Director at fepsy Basel; Lecturer at FHNW
Data updated
Research Footprint
Erich Studerus appears in 8 tracked papers (2010–2024), most studied alongside Psilocybin, MDMA and Ayahuasca, across Healthy Volunteers, Anxiety Disorders and Personality & Trait Factors.
Most-cited paper: Psychometric evaluation of the altered states of consciousness rating scale (OAV) (685 citations).
Frequent co-authors: Franz Vollenweider, Matthias Kometer and Patrick Vizeli.
Background & Research
Erich Studerus is a Swiss psychologist whose work has focused on predicting and characterizing subjective and neurophysiological responses to psychedelics and entactogens in healthy volunteers. He has been affiliated with the University of Basel psychiatric research environment and is listed as Scientific Director at fepsy Basel, with current teaching activity at FHNW. His publications include pooled analyses and experimental studies on psilocybin, LSD, MDMA, and ayahuasca.
Key Impact
He is a recurring author on influential human psychedelic studies, especially on psilocybin, LSD, MDMA, and ayahuasca effects and predictors of response.
Collaboration Network
20 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Erich Studerus is associated with.
FHNW
The University of Applied Sciences and Arts Northwestern Switzerland (FHNW) is a public Swiss university of applied sciences offering practice‑oriented bachelor’s and master’s programs across multiple schools (engineering, business, life sciences, art & design, education, etc.) and conducting applied research, continuing education, and regional services.
View stakeholder →University of Basel
academicThe University of Basel Department of Biomedicine hosts the Liechti Lab research group, headed by Matthias Liechti. Research here is primarily focused on the pharmacology of psychoactive substances. Much of the clinical research exploring the effects of LSD is taking place at University Hospital Basel. Researchers here are exploring the potential of LSD to treat Cluster Headache, Major Depressive Disorder and anxiety associated with severe somatic diseases. Professor Liechti is also conducting studies comparing the acute effects of LSD, psilocybin and mescaline, and MDMA for fear extinction.
View stakeholder →